rs2270993

This is a splice region variant variant in the PTPRJ gene.

Research that mentions this SNP (1)

High‐resolution loss of heterozygosity screening implicates PTPRJ as a potential tumor suppressor gene that affects susceptibility to non‐hodgkin's lymphoma
AssociationN=207Carlos Aya‐Bonilla et al.(2013)· Genes, Chromosomes and Cancer

High-resolution LOH analysis identified PTPRJ (11p11.2) as a potential tumor suppressor gene in non-Hodgkin's lymphoma, with loss of heterozygosity in 38% of cases (33% DLBCL, 43% FL). Coding SNPs rs2270993 (G973A), rs2270992 (T1054C), rs1566734 (A1182C), and rs4752904 (G2971C) showed significant allelic frequency differences between LOH and retention cases, with haplotype GTCG conferring protective effects (OR=0.33, p=0.021) and GCAC associated with increased risk in LOH cases.

Traits studied:Diffuse Large B-Cell LymphomaFollicular LymphomaNon-Hodgkin's Lymphoma

About PTPRJ

The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes, including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP possesses an extracellular region containing five fibronectin type III repeats, a single transmembrane region, and a single intracytoplasmic catalytic domain, and thus represents a receptor-type PTP. This protein is present in all hematopoietic lineages, and was shown to negatively regulate T cell receptor signaling possibly through interfering with the phosphorylation of Phospholipase C Gamma 1 and Linker for Activation of T Cells. This protein can also dephosphorylate the PDGF beta receptor, and may be involved in UV-induced signal transduction. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

View all PTPRJ variants →

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…